Scienture Holdings, Inc. (NASDAQ:SCNX) shares jumped 21.25% to $0.4046 in overnight trading at the time of writing, adding to a 0.48% Thursday surge.
Naloxone Spray Nears Market Launch
The stock move came after the New York-based comprehensive health services and pharmaceutical company announced before Thursday’s market open that it had completed manufacturing of commercial launch inventory for REZENOPY (naloxone hydrochloride) Nasal Spray 10 mg. The company said shipments to U.S. pharmaceutical wholesalers are expected to begin later this month.
REZENOPY is the highest-dose Food and Drug Administration-approved naloxone nasal spray available in the U.S. It delivers a 10 mg dose through a single-use device to reverse known or suspected opioid overdoses, including those involving powerful synthetic opioids. The FDA approved the treatment in April 2024.
Retail availability is expected in August, with the company working alongside wholesale distribution partners nationwide.
